H2024: Joint Program: Section on Infectious Diseases and Section on Epidemiology, Public Health and Evidence
New Interventions to Prevent RSV Disease in Infants and Young Children

Saturday, September 28, 2024

1:00 PM - 4:45 PM EDT

Location: Orange County Convention Center, West Building, W207B

CME 3.25

Topic(s): Infectious Diseases; Epidemiology

View full agenda here

Rx (Pharmacology): 2.75

Respiratory syncytial virus (RSV) disease is an important cause of morbidity and mortality among young children. Nirsevimab for infants and RSV vaccination of pregnant women have been developed to prevent RSV disease in young children. This program will review these interventions and potential challenges in rolling them out.
This session is part of the Passport to Pediatric Medical Subspecialties Pilot Program! To learn more, see here.

Faculty(s)

Elizabeth D. Barnett, MD, FAAP (she/her/hers)

Chief, Section of Pediatric Infectious Diseases
Boston Medical Center
Sharon, Massachusetts, United States
Laura Hammitt, MD (she/her/hers)

Johns Hopkins School of Public Health
Charlene Wong, MD MSHP

Senior Advisory for Health Strategy
Centers for Disease Control and Prevention
Manisha Patel, MD, MS, MBA

Chief Medical Officer
National Center for Immunization and Respiratory Diseases, CDC

H2024: Joint Program: Section on Infectious Diseases and Section on Epidemiology, Public Health and EvidenceNew Interventions to Prevent RSV Disease in Infants and Young Children

Faculty(s)

H2024: Joint Program: Section on Infectious Diseases and Section on Epidemiology, Public Health and Evidence
New Interventions to Prevent RSV Disease in Infants and Young Children